Clinical Trials
Olanzapine has greater efficacy but more side effects than ziprasidone
Published in Clinical Trials Week, December 26th, 2005
In a "multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia" in the United States, the "efficacy and safety of olanzapine were compared with those of ziprasidone."
"Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone," according to A. Breier and coauthors at Lilly Research Laboratories. "The primary efficacy measure was the Positive and Negative Syndrome Scale total score," while "secondary efficacy...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-12-26)
More Articles from Clinical Trials Week
- Clinical Trials
Once weekly dalbavancin as effective as twice daily linezolid for complicated SSSIs - Drug Development
Enrollment completed in phase III study of Entereg in postoperative ileus - Urology
Intradetrusor botulinum toxin B effective for patients with adverse reactions to toxin A - Actinic Keratosis
Phase IIa trial results show PEP005 gel effective on precancerous skin condition - Allergy & Immunology
Olopatadine eyedrop treatment ameliorate ocular symptoms in most patients - Bladder Cancer
Urine telomerase activity levels used to diagnose bladder cancer - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
